Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH
Pregabalin Capsules have an estimated market size of US $244 million for twelve months ending Sep 2022 according to IQVIA
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
The project will generate and supply green energy to fulfill about 50% present consumption of the company
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
Global pharmaceutical company having a surgical business concept incepted in Dubai
Subscribe To Our Newsletter & Stay Updated